Ernexa Therapeutics Inc. (ERNA)
NASDAQ: ERNA · Real-Time Price · USD
0.2005
-0.0100 (-4.75%)
At close: Apr 2, 2026, 4:00 PM EDT
0.2000
-0.0005 (-0.25%)
After-hours: Apr 2, 2026, 7:16 PM EDT
Ernexa Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
7
Market Cap
5.85M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 582.00K | 514.00K | 755.88% |
| Dec 31, 2023 | 68.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | 24.06M | 194.00K | 0.81% |
| Dec 31, 2011 | 23.87M | -1.44M | -5.69% |
| Dec 31, 2010 | 25.31M | -505.00K | -1.96% |
| Dec 31, 2009 | 25.81M | -1.68M | -6.12% |
| Dec 31, 2008 | 27.50M | -3.05M | -9.97% |
| Dec 31, 2007 | 30.54M | -2.44M | -7.41% |
| Dec 31, 2006 | 32.99M | 2.24M | 7.27% |
| Dec 31, 2005 | 30.75M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Immuron | 4.99M |
| Xenetic Biosciences | 2.98M |
| XTL Biopharmaceuticals | 968.00K |
| Addex Therapeutics | 198.82K |
| Cardio Diagnostics Holdings | 14.83K |
ERNA News
- 2 days ago - Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026 - GlobeNewsWire
- 5 weeks ago - Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series - GlobeNewsWire
- 7 weeks ago - Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering - GlobeNewsWire
- 2 months ago - Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA - GlobeNewsWire
- 2 months ago - Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program - GlobeNewsWire
- 3 months ago - Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer - GlobeNewsWire
- 4 months ago - Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer - GlobeNewsWire
- 4 months ago - Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting - GlobeNewsWire